A leading company in the development and production of interventional cardiovascular and endovascular devices, Cordis, has acquired MedAlliance, a company based in Switzerland that specialises in the development of drug-eluting balloon technology.
The company’s portfolios for coronary and peripheral vascular disease are strengthened by this acquisition because, as they anticipate, SELUTION SLRTM (Sustained Limus Release) Drug-Eluting Balloons (DEB) will be the first Sirolimus DEB to be commercialised in important regions.
“This acquisition is key in advancing Cordis’ legacy of cardiovascular innovation,” said Shar Matin, CEO of Cordis. “We are creating leverage by joining the MedAlliance team and their world-class innovation with the reach and breadth of Cordis’ global infrastructure. This combination will add value to millions of patients and clinicians, revolutionizing vascular care.”
In the creation and production of interventional cardiovascular and endovascular technologies, Cordis is a world leader. The flagship product family offered by MedAlliance’s ground-breaking sustained sirolimus drug-eluting balloon (DEB) programme, SELUTION SLRTM (Sustained Limus Release), complements Cordis’ current product line and their knowledge of sales, marketing, and distribution.
“The Cordis acquisition will accelerate access to this breakthrough technology for patients suffering from coronary and peripheral disease around the globe,” said Jeffrey B. Jump, Founder, Chairman and CEO of MedAlliance. “The team set out to disrupt the coronary and peripheral markets and provide physicians with a new safe and effective technology. The arsenal of SELUTION SLR™ DEB clinical data is designed to change medical practice and improve patient outcomes.”
Customers of Cordis will gain from the extensive clinical study programme and publication plan that MedAlliance has implemented in order to continue Cordis’ tradition of bringing cutting-edge products to patients.
With more than 60 years of experience developing and manufacturing cutting-edge cardiovascular technologies to treat millions of patients, Cordis is a global leader in the field of interventional vascular technology. Cordis built a strong global footprint with operations in more than 70 nations around the world and established a legacy of innovation in high-quality and minimally invasive cardiovascular products. Cordis has a reputation for clinical expertise, training, and service.
The headquarters of MedAlliance are in Nyon, Switzerland. It focuses on the creation of novel technologies and the marketing of high-tech drug-device combinations, initially for the treatment of peripheral and coronary artery disease.